GLOBAL X ETFs ICAV
(an umbrella fund with segregated liability between sub-funds)
10 Earlsfort Terrace
Dublin 2 D02 T380
Ireland
This document is important and requires your immediate attention. If you are in any doubt as to the action you should take, you should seek advice from your investment consultant or other professional advisors. This document has not been reviewed by the Central Bank of Ireland (the "Central Bank").
If you have sold or transferred all of your shares in Global X Hydrogen UCITS ETF (the Fund"), please pass this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.
Capitalised terms used herein shall bear the same meaning as defined in the prospectus of Global X ETFs ICAV (the "ICAV) dated 6 May 2021, as amended by addenda thereto dated 13 December 2021 and 13 May 2022 respectively, (the "Prospectus") and the supplement in respect of the Fund, dated 20 July 2022 (the "Supplement"). Copies of the Prospectus and Supplement are available upon request during normal business hours from the registered office of the ICAV.
29 September 2022
RE: Notification of amendments to the investment policy of the Fund
Dear Investors
The ICAV is an open-ended investment vehicle with variable capital organised under the laws of Ireland and is authorised by the Central Bank pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended. The Fund is a sub-fund of the ICAV.
The Supplement discloses that the Fund, by holding each equity security in approximately the same proportion as its weighting in the Index, in accordance with its investment policy, may have exposure to, or invest up to, 20% of the Net Asset Value of the Fund in stocks issued by the same body. It is proposed that the Supplement be updated to reflect the proposal to allow this 20% limit to be raised to 35% of the Net Asset Value of the Fund for a single issuer in exceptional market conditions, which may include the dominance of a particular issuer in the relevant market.
It is proposed that the changes to the Supplement outlined above will take effect on, or around, 10 October 2022, subject to the approval of the Central Bank.
Should you have any questions relating to the changes detailed above, you should contact your local
agent, or (if none) Global X ETFs on +44 (0)20 4529 2551 or europe@globalxetfs.com, or alternatively you should contact your investment consultant, tax adviser and/or legal adviser as appropriate.
Yours faithfully,
_______________
For and on behalf of
Global X ETFs ICAV
Registered Office: as above
Registration Number: C435449
Directors: Feargal Dempsey, Mary Canning and Luis Berruga (USA)
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.